(June 3, 2016, 7:55 AM EDT) -- WASHINGTON, D.C. — Sandoz Inc. argues in a May 17 brief to the U.S. Supreme Court that an appellate court properly concluded both that Sandoz did not violate the Biologics Price Competition and Innovation Act (BPCIA) by withholding its application and that Amgen Inc. and Amgen Manufacturing Ltd.’s (Amgen, collectively) unfair competition law (UCL) and conversion claims failed for independent state law reasons (Amgen, Inc. and Amgen Manufacturing, Ltd. v. Sandoz, Inc., No. 15-1195, U.S. Sup.)....